Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy

SIMPLE SUMMARY: A new subgroup of breast cancer patients with different survival outcomes, even before new treatment options have been approved, which can be easily differentiated immunohistochemically, has recently received great attention. The approval of trastuzumab deruxtecan in August 2022 by t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pöschke, Patrik, Fasching, Peter A., Adler, Werner, Rübner, Matthias, Beckmann, Matthias W., Hack, Carolin C., Heindl, Felix, Hartmann, Arndt, Erber, Ramona, Gass, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571544/
https://www.ncbi.nlm.nih.gov/pubmed/37835372
http://dx.doi.org/10.3390/cancers15194678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571544/
https://www.ncbi.nlm.nih.gov/pubmed/37835372
http://dx.doi.org/10.3390/cancers15194678

Ejemplares similares